2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precision Oncology 2024, 8: e2400287. PMID: 39499893, DOI: 10.1200/po.24.00287.Peer-Reviewed Original ResearchConceptsNeoadjuvant cisplatin-based chemotherapyMuscle-invasive bladder cancerProgression-free survivalDDR alterationsDNA damage response alterationPathological responseBladder cancerDNA damage responseAssociated with pathological responseNeoadjuvant chemotherapy sensitivityPretreatment tumor specimensPathological response rateCisplatin-based chemotherapyDNA damage response genesEstimates of hazard ratiosOverall survivalRadical cystectomyTumor specimensPerformance statusClinical stageChemotherapy sensitivityCox regressionHazard ratioNext-generation sequencingPatientsAdjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma
Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, Pruthi D, Bergerot C, Tripathi A, Lerner S, Thompson I, Lara P, Pal S. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma. JAMA Network Open 2024, 7: e2425288. PMID: 39106067, PMCID: PMC11304111, DOI: 10.1001/jamanetworkopen.2024.25288.Peer-Reviewed Original ResearchConceptsChromophobe renal cell carcinomaRecurrence-free survivalPapillary renal cell carcinomaRenal cell carcinomaNon-clear cell renal cell carcinomaResected renal cell carcinomaCell renal cell carcinomaOverall survivalWeeks of treatmentCell carcinomaAdverse eventsClinical trialsHazard ratioPhase 3 randomized clinical trialWeeks of everolimusHigher adverse eventsRate of adverse eventsIntermediate-high riskIntervention groupVery-high-riskCox regression modelsPotential treatment benefitsClinical trial dataTreatment-naivePartial nephrectomy
2023
Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses
DiNardo A, Arditi M, Kamat A, Koster K, Carrero S, Nishiguchi T, Lebedev M, Benjamin A, Avalos P, Lozano M, Moule M, McCune B, Herron B, Ladki M, Sheikh D, Spears M, Herrejon I, Dodge C, Kumar S, Hutchison R, Ofili T, Opperman L, Bernard J, Lerner S, Udeani G, Neal G, Netea M, Cirillo J. Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials 2023, 24: 636. PMID: 37794431, PMCID: PMC10548680, DOI: 10.1186/s13063-023-07662-w.Peer-Reviewed Original ResearchConceptsBacillus Calmette-GuerinBacillus Calmette-Guerin vaccineSARS-CoV-2 infectionRandomized controlled trialsSARS-CoV-2BCG vaccinationClinical course of SARS-CoV-2 infectionCourse of SARS-CoV-2 infectionTreatment groupsAdministration of BCG vaccineKaplan-Meier curvesCox proportional hazards modelsEffect of BCG vaccinationInfection in vitroInfection of healthcare workersEvidence of SARS-CoV-2 infectionHealthcare workersMulti-center randomized controlled trialProportional hazards modelImmunological markersIntradermal administrationHazard ratioNon-specific effectsImmune responseHigh risk